Sedation Clinical Trial
Official title:
Dexmedetomidine Sedation in Pediatric Intensive Care Unit
Dexmedetomidine is a highly selective α2-agonist with hypnotic, analgesic, and anxiolytic properties. Despite off-label administration, dexmedetomidine has found a niche in critically ill mechanically ventilated neonates and infants because of its minimal effects on respiratory function at sedative doses, facilitating early extubation and fast-track postoperative care.
Critically ill children require sedation for comfort and to facilitate mechanical ventilation
and interventions. The ideal sedative agent for use in critically ill children has to be
effective and short-acting, of rapid onset of action, lacks active metabolites, does not
accumulate in patients with renal or hepatic dysfunction, has minimal to no cardiovascular or
respiratory adverse effects, and has few drug interactions.
Dexmedetomidine is a highly selective α2-agonist with hypnotic, analgesic, and anxiolytic
properties. Despite off-label administration, dexmedetomidine has found a niche in critically
ill mechanically ventilated neonates and infants because of its minimal effects on
respiratory function at sedative doses, facilitating early extubation and fast-track
postoperative care.
The only FDA approved indication of dexmedetomidine is sedation of intubated mechanically
ventilated adults for less than 24h. However, the literature is full of many research studies
that investigated the use off-lable use of dexmedetomidine for sedation more than 24h in both
adult and pediatric population and proved its safety and effectiveness.
The aim of this study will be to investigate the safety and efficacy of dexmedetomidine in
two different doses in sedation for critically ill mechanically ventilated infants with
respiratory failure for 72h duration.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT03399019 -
Bispectral Index(BIS) on Depth of Sedation With Dexmedetomidine, Propofol and Midazolam During Spinal Anesthesia
|
N/A | |
| Completed |
NCT03220880 -
Intranasal Dexmedetomidine Sedation in Children for Non-painful Procedures
|
||
| Recruiting |
NCT04820205 -
Comparison of Oral Chloral Hydrate and Combination of Intranasal Dexmedetomidine and Ketamine for Procedural Sedation in Children
|
N/A | |
| Recruiting |
NCT04549623 -
End-Tidal Carbon Dioxide Monitoring Device for Sedation During Endoscopic Ultrasonography
|
N/A | |
| Recruiting |
NCT04822064 -
Comparison of Oral Chloral Hydrate and Combination of Intranasal Dexmedetomidine and Ketamine for Rescue After Failed Pediatric Procedural Sedation
|
N/A | |
| Completed |
NCT01527903 -
A Comparison Between Propofol-Remifentanil and Midazolam-Remifentanil Sedation in the Intensive Care Unit
|
Phase 4 | |
| Completed |
NCT01001533 -
Assess the Ability of Electrical Cardiometry to Trend Hemodynamic Variables During Dexmedetomidine Sedation
|
N/A | |
| Completed |
NCT00747721 -
Pharmacokinetics of Dexmedetomidine During Prolonged Infusion in ICU
|
Phase 1 | |
| Completed |
NCT00158873 -
Pharmaco-Economic Study Of Ultiva In Intensive Care Unit(ICU)Subjects
|
Phase 4 | |
| Terminated |
NCT00205517 -
Sedation and Psychopharmacology in Critical Care
|
N/A | |
| Recruiting |
NCT04096768 -
The Use of Ketamine and Dexmedetomidine in Intensive Care Sedation
|
Phase 3 | |
| Active, not recruiting |
NCT05082623 -
The Effect of Music on Delirium, Pain, Need of Sedation, Anxiety and Vital Parameters
|
N/A | |
| Suspended |
NCT03285165 -
Cerebral Vascular Effects of Dexmedetomidine Versus Propofol Sedation in Intubated Mechanically Ventilated ICU Patients
|
Phase 2/Phase 3 | |
| Active, not recruiting |
NCT04788589 -
Sedation and Ventilator Weaning Protocol in PICU
|
N/A | |
| Completed |
NCT03425474 -
Study of Remimazolam Tosilate in Patients Undergoing Diagnostic Upper GI Endoscopy
|
Phase 3 | |
| Recruiting |
NCT06061159 -
The ED95 of Single Intravenous Bolus Remimazolam Besylate in Pediatric Patients During General Anesthesia Induction
|
Phase 4 | |
| Completed |
NCT06449365 -
Comparison of Intravenous V/S Nasal Atomizer Delivery of Midazolam for Conscious Sedation for No-scalpel Vasectomy
|
Phase 4 | |
| Completed |
NCT02171910 -
Doxapram as an Additive to Propofol Sedation in Sedation for ERCP
|
Phase 4 | |
| Completed |
NCT02211118 -
Sedation and Physiological Effects of Intranasal Dexmedetomidine in Severe COPD
|
Phase 4 | |
| Completed |
NCT01694745 -
EUROpean Pain Audit In Neonates
|
N/A |